Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04648696 · ClinicalTrials.gov registry record · Phase 4
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT04648696: Clinical Trial Phase 4 study, sponsored by Wake Forest University Health Sciences.
NCT04648696 is a Phase 4 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 8 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04648696, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
Evaluate the safety and outcomes associated between the two treatment modalities
Primary Outcome
Number of Subjects with any increase in Serum creatinine by 50% from baseline, an increase in Scr by 0.5 mg/dL, or an increase in Scr by 0.3 mg/dL on two consecutive measurements
Interventions
- DRUG Vancomycin CI
- DRUG Vancomycin II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 4 |
Why NCT04648696 stopped before completion
NCT04648696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Vancomycin CI is the first listed.
NCT04648696 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04648696 about?
NCT04648696 is a clinical study titled "Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin". Evaluate the safety and outcomes associated between the two treatment modalities
What is the current status of trial NCT04648696?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2021-03-03. Estimated completion is 2022-10-31.
What interventions are being tested in trial NCT04648696?
The interventions under investigation include: Vancomycin CI (DRUG), Vancomycin II (DRUG).
Who is sponsoring clinical trial NCT04648696?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04648696's enrollment target sits among peer trials
8 1972nd of 2000 higher than 20 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI